Verona is enjoying an “exceptionally strong” market debut for its first product offering, Ohtuvayre, having outstripped analyst expectations for the novel
In its first seven weeks since launch, the first-in-class dual phosphodiesterase 3/4 inhibitor brought in $5.6m, and net sales for October have exceeded those for the third quarter. The revenues were more than double consensus estimates at $2m+